Education
About Us
Working with TipRanks
Follow Us
Actinium Pharmaceuticals (ATNM)
:ATNM
ATNM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.03 - $10.24
Previous CloseN/A
Volume63.23K
Average Volume (3M)228.76K
Market Cap
$48.35M
Enterprise Value-$18.53M
Total Cash (Recent Filing)$13.67M
Total Debt (Recent Filing)$262.59K
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 24, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding31,195,890
10 Day Avg. Volume367,163
30 Day Avg. Volume228,759
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)596.96
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-228.83
Enterprise Value/Ebitda0.42
Forecast
1Y Price Target
$6.00Price Target Upside287.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe planned clinical trials will evaluate Actimab-A in combination with Keytruda and Opdivo for head and neck squamous cell carcinoma and non-small cell lung cancer, potentially enhancing the efficacy of these treatments.
Market OpportunitiesUse of Actimab-A in earlier lines of treatment could open significantly larger market opportunities for Actinium Pharmaceuticals.
Research CollaborationThe new research agreement with Memorial Sloan Kettering Cancer Center aims to explore Actimab-A in combination with other targeted therapies, which could expand its potential in treating acute myeloid leukemia (AML).
Bears Say
Development SetbacksDespite setbacks, favorable clinical and regulatory updates are expected to offset negative sentiment, supported by European approval and royalty streams.
Regulatory ChallengesThere was a significant regulatory setback for Iomab-B in the U.S., affecting its development.
---
Ownership Overview
4.90%
Insiders
8.77% Mutual Funds
1.21% Other Institutional Investors
75.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATNM FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was $1.03 and its highest was $10.24 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Actinium Pharmaceuticals’s market cap is $48.35M.
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Nov 24, 2025 which is in 244 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 14, 2025. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.374 by -$0.046.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate is -0.37.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 31,195,890 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.374. Following the earnings report the stock price went up 2.5%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Currently, no hedge funds are holding shares in ATNM
---
Actinium Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (287.10% Upside)
$6.00 (287.10% Upside)
Blogger Sentiment
Bullish
ATNM Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 50.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.98%
12-Months-Change
Fundamentals
Return on Equity
-100.05%
Trailing 12-Months
Asset Growth
-7.68%
Trailing 12-Months
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
---
ATNM Stock 12 Month Forecast
Average Price Target
$6.00
▲(287.10% Upside)
Technical Analysis
Best Analysts Covering ATNM
1 Year
1 Year Success Rate
5/18 ratings generated profit
1 Year Average Return
-41.10%
reiterated a buy rating 13 days ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -41.10% per trade.
---